Alexander Valdman

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Jag disputerade 2005 vid Karolinska Institutet på en avhandling om prostatacancer. Efter en postdoc period på Johns Hopkins i Baltimore, USA 2006-2007 återkom jag till Radiumhemmet på Karolinska Universitetssjukhuset där jag blev specialist i onkologi 2012 och sedermera docent i onkologi vid Karolinska Institutet.

Mitt forskningsområde är strålbehandling av bäckencancertumörer. Min forskning fokuserar på att studera kliniska effekter av olika strålslag som kan ge patienter en mer effektiv onkologisk behandling med mer skonsam biverkningsprofil.

Forskningsbeskrivning

Ansvarig huvudprövare (PI) för forskningsstudien PRORECT (NCT04525989) www.prorect.se

Artiklar

Article: CANCER. 2025;131(16):e70045
Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer
Falagario UG; Pellegrino F; Abbadi A; Bjornebo L; Valdman A; Eriksson MH; Zelic R; Carrieri G; Gandaglia G; Briganti A; Montorsi F; Aly M; Palsdottir T; Eklund M; Nordstrom T; Gronberg H; Akre O; Wiklund P; Lantz A
Journal article: CANCERS. 2025;17(16):2627
An In Silico Feasibility Study of Dose-Escalated Hypofractionated Proton Therapy for Rectal Cancer
Almhagen E; Alkhiat A; Sorcini B; Alpsten F; Kronborg CJS; Ronde HS; Guren MG; Pilskog S; Valdman A
Journal article: ADVANCES IN RADIATION ONCOLOGY. 2025;10(6):101766
Association of Circulating Inflammatory Biomarker Levels and Toxicity in Patients Undergoing Pelvic Radiation for Cancer: A Critical Review
Fesse P; Svensson P-A; Zackrisson B; Valdman A; Fransson P; Grankvist K; Kristensen I; Langegard U; Ohlsson-Nevo E; Sjovall K; Akeflo L; Ahlberg K
Article: BMJ OPEN. 2025;15(4):e100356
Contact radiotherapy for rectal cancer (CORRECT): study protocol for a multicentre randomised phase II trial
Nilsson PJ; Folkesson J; Marsk R; Radu C; Stratulat I; Blomqvist L; Martling A; Valdman A
Article: PHYSICS AND IMAGING IN RADIATION ONCOLOGY. 2024;32:100663
Comparing robust proton versus online adaptive photon radiotherapy for short-course treatment of rectal cancer
Hundvin JA; Lilleoren UH; Valdman A; Sorcini B; Brennsaeter JA; Boer CG; Pettersen HES; Redalen KR; Loes IM; Pilskog S
Journal article: BJS-BRITISH JOURNAL OF SURGERY. 2024;111(9):znae241
Surgical outcomes following total neoadjuvant therapy in rectal cancer with short-course radiotherapy using protons or photons: initial safety data from the PRORECT randomized trial
Valdman A; Marsk R; Karimi M; Asklid D; Brattstrom D; Ostling Palme J; Martling A; Nilsson PJ
Journal article: BJS-BRITISH JOURNAL OF SURGERY. 2024;111:znae175.053
Surgical outcomes after TNT in rectal cancer with short-course radiotherapy using protons or photons: Early results from the randomised PRORECT trial
Nilsson PJ; Marsk R; Karimi M; Asklid D; Brattstrom D; Ostling-Palme J; Martling A; Valdman A
Journal article: INTERNATIONAL JOURNAL OF PARTICLE THERAPY. 2024;12:100134
O021 / #131 PRE-PLANNED EARLY SAFETY ANALYSIS OF THE PRORECT TRIAL
Valdman A; Alpsten F; Färlin J; Sorcini B
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e1213
PD57-12 PSA RESPONSE AFTER RADIOTHERAPY. IS THERE A DEFINITION OF PSA PERSISTENCE AFTER RT?
Falagario UG; Pellegrino F; Abbadi A; Björnebo L; Valdman A; Carrieri GG; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordström T; Grönberg H; Wiklund P; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2024;211(5S):e623
PD29-12 THE IMPACT OF THE TIME ELAPSED BETWEEN PRIMARY TREATMENT AND BCR ON CANCER SPECIFIC MORTALITY IN PATIENTS WHO EXPERIENCED BCR AFTER PRIMARY TREATMENT
Pellegrino F; Falagario UG; Abbadi A; Björnebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordström T; Grönberg H; Lantz A; Wiklund P
Journal article: EUROPEAN UROLOGY. 2024;85:s1402-s1403
PSA response after radiotherapy. Is there a definition of PSA persistence after RT?
Falagario UG; Pellegrino F; Abbadi A; Bjornebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Wiklund P; Lantz A
Journal article: EUROPEAN UROLOGY. 2024;85:s1534-s1535
The impact of the time elapsed between primary treatment and BCR on cancer specific mortality in patients who experienced BCR after primary treatment
Pellegrino F; Falagario UG; Abbadi A; Bjornebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Lantz A; Wiklund P
Article: JAMA NETWORK OPEN. 2023;6(9):e2332900
Biochemical Recurrence and Risk of Mortality Following Radiotherapy or Radical Prostatectomy
Falagario UG; Abbadi A; Remmers S; Bjornebo L; Bogdanovic D; Martini A; Valdman A; Carrieri G; Menon M; Akre O; Eklund M; Nordstrom T; Gronberg H; Lantz A; Wiklund P
Article: BRACHYTHERAPY. 2023;22(3):407-415
Validation of automated post-adjustments of HDR prostate brachytherapy treatment plans by quantitative measures and oncologist observer study
Dohlmar F; Moren B; Sandborg M; Smedby O; Valdman A; Larsson T; Tedgren AC
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e419
PD15-04 PREDICTION OF PROSTATE CANCER SPECIFIC MORTALITY IN MEN UNDERGOING RADIOTHERAPY WITH OR WITHOUT HORMONAL TREATMENT, RISK STRATIFICATION BASED ON CLINICAL CHARACTERISTICS AND PSA TREATMENT RESPONSE
Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Wiklund P; Lantz A
Journal article: INVESTIGATIVE UROLOGY. 2023;209(Supplement 4):e214
MP17-06 VALIDATION OF EAU RISK GROUPS FOR BIOCHEMICAL RECURRENCE AFTER RADIOTHERAPY AND RADICAL PROSTATECTOMY FOR PREDICTION OF PROSTATE CANCER MORTALITY
Falagario U; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Article: CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 2023;39:100562
Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal cancer (PRORECT): Initial dosimetric experience
Pedone C; Sorcini B; Staff C; Farlin J; Fokstuen T; Frodin J-E; Nilsson PJ; Martling A; Valdman A
Journal article: EJSO. 2023;49(2):e132
Multidisciplinary, consensus-based target volume definition in locally recurrent rectal cancer
Piqeur F; Hupkens B; Nordkamp S; Witte M; Meijnen P; Ceha H; Berbee M; Dieters M; Heyman S; Valdman A; Nilsson M; Nederend J; Rutten H; Burger P; Peulen H
Journal article: EUROPEAN UROLOGY. 2023;83:s1613-s1614
Prediction of prostate cancer specific mortality in men undergoing radiotherapy with or without hormonal treatment, risk stratification based on clinical characteristics and PSA treatment response
Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Wiklund P; Lantz A
Journal article: EUROPEAN UROLOGY. 2023;83:s379-s380
A0266 Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality
Falagario UG; Bogdanovic D; Björnebo L; Abbadi A; Valdman A; Eklund M; Nordström T; Aly M; Grönberg H; Lantz A; Wiklund P
Article: RADIOTHERAPY AND ONCOLOGY. 2022;177:214-221
Development of a consensus-based delineation guideline for locally recurrent rectal cancer
Piqeur F; Hupkens BJP; Nordkamp S; Witte MG; Meijnen P; Ceha HM; Berbee M; Dieters M; Heyman S; Valdman A; Nilsson MP; Nederend J; Rutten HJT; Burger JWA; Marijnen CAM; Peulen HMU
Article: PHYSICS AND IMAGING IN RADIATION ONCOLOGY. 2022;22:67-72
Autosegmentation based on different-sized training datasets of consistently-curated volumes and impact on rectal contours in prostate cancer radiation therapy
Olsson CE; Suresh R; Niemela J; Akram SU; Valdman A
Article: PHYSICS AND IMAGING IN RADIATION ONCOLOGY. 2019;11:88-91
Initial experience with introducing national guidelines for CT- and MRI-based delineation of organs at risk in radiotherapy
Olsson C; Nyholm T; Wieslander E; Onjukka E; Gunnlaugsson A; Reizenstein J; Johnsson S; Kristensen I; Skonevik J; Karlsson M; Isacsson U; Flejmer A; Abel E; Nordstrom F; Nystrom L; Bergfeldt K; Zackrisson B; Valdman A
Journal article: JOURNAL OF RADIATION ONCOLOGY. 2019;8(2):225-231
Salvage radiation therapy following radical prostatectomy in Stockholm County in 2008-2016
Falk J; Aly M; Berglund A; Nordstrom T; Valdman A
Article: MEDICAL PHYSICS. 2018;45(3):1210-1221
Quantitative evaluation of potential irradiation geometries for carbon-ion beam grid therapy
Tsubouchi T; Henry T; Ureba A; Valdman A; Bassler N; Siegbahn A
Article: TECHNOLOGY IN CANCER RESEARCH & TREATMENT. 2017;16(6):749-757
Proton Grid Therapy: A Proof-of-Concept Study
Henry T; Ureba A; Valdman A; Siegbahn A
Article: RADIOTHERAPY AND ONCOLOGY. 2016;119(2):344-350
A national approach for automated collection of standardized and population-based radiation therapy data in Sweden
Nyholm T; Olsson C; Agrup M; Bjork P; Bjork-Eriksson T; Gagliardi G; Grinaker H; Gunnlaugsson A; Gustafsson A; Gustafsson M; Johansson B; Johnsson S; Karlsson M; Kristensen I; Nilsson P; Nystrom L; Onjukka E; Reizenstein J; Skonevik J; Soderstrom K; Valdman A; Zackrisson B; Montelius A
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2010;44(6):371-377
Beta-tubulin III expression in prostate cancer
Egevad L; Valdman A; Wiklund NP; Seve P; Dumontet C
Article: APMIS. 2010;118(5):360-365
Distribution of Foxp3-, CD4-and CD8-positive lymphocytic cells in benign and malignant prostate tissue
Valdman A; Jaraj SJ; Comperat E; Charlotte F; Roupret M; Pisa P; Egevad L
Article: CELLULAR ONCOLOGY. 2010;32(1):39-44
Clinical Significance of Intratumoral CD8+ Regulatory T Cells in Prostate Carcinoma
Comperat E; Egevad L; Camparo P; Roupret M; Vaessen C; Valdman A; Jonmarker S; Capron F; Cussenot O; Charlotte F
Article: CELLULAR ONCOLOGY. 2009;31(6):367-374
Expression of Redox Pathway Enzymes in Human Prostatic Tissue
Valdman A; Haggarth L; Cheng L; Lopez-Beltran A; Montironi R; Ekman P; Egevad L
Article: CELLULAR ONCOLOGY. 2009;31(3):137-142
Endothelin-1 Expression in Prostate Cancer and High Grade Prostatic Intraepithelial Neoplasia
Rosenblatt R; Valdman A; Cheng L; Lopez-Beltran A; Montironi R; Ekman P; Egevad L
Article: APMIS. 2008;116(10):888-895
Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer
Glaessgen A; Jonmarker S; Lindberg A; Nilsson B; Lewensohn R; Ekman P; Valdman A; Egevad L
Article: APMIS. 2008;116(6):491-498
Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue
Jonmarker S; Glaessgen A; Culp WD; Pisa P; Lewensohn R; Ekman P; Valdman A; Egevad L
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2008;42(5):484-487
Atypical stromal hyperplasia of the prostate
Egevad L; Carbin B-E; Castellanos E; Hellstrom M; Valdman A
Article: VIRCHOWS ARCHIV. 2006;449(3):297-301
Tissue shrinkage after fixation with formalin injection of prostatectomy specimens
Jonmarker S; Valdman A; Lindberg A; Hellstrom M; Egevad L
Article: DIAGNOSTIC CYTOPATHOLOGY. 2006;34(5):317-322
Cytological features of prostatic intraepithelial neoplasia
Valdman A; Jonmarker S; Ekman P; Egevad L
Article: EUROPEAN UROLOGY. 2005;48(5):852-857
Ezrin expression in prostate cancer and benign prostatic tissue
Valdman A; Fang XL; Pang ST; Nilsson B; Ekman P; Egevad L
Article: PROSTATE. 2004;60(4):367-371
Pim-I expression in prostatic intraepithelial neoplasia and human prostate cancer
Valdman A; Fang XL; Pang ST; Ekman P; Egevad L
Journal article: JOURNAL OF UROLOGY. 2004;171(4):110
PIM-1 expression in prostatic intraepithelial neoplasia and human prostate cancer
Valdman A; Fang XL; Pang ST; Ekman P; Egevad L
Article: UROLOGY. 2004;63(3):609-612
Expression of ezrin in prostatic intraepithelial neoplasia
Pang ST; Fang XL; Valdman A; Norstedt G; Pousette Å; Egevad L; Ekman P
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2003;22(5):1003-1007
Mutation analysis of the BRG1 gene in prostate cancer clinical samples
Valdman A; Nordenskjöld A; Fang XL; Naito A; Al-Shukri S; Larsson C; Ekman P; Li CD
Journal article: EXPERIMENTAL ONCOLOGY. 2002;24(3):203-207
The effects of tumor activity on urinary concentration of matrix metalloproteinases 2 and 9 in bladder cancer
Daniltchenko D; Gerhards S; Jung K; Koenig F; Valdman A; Al-Shukri S; Loening SA
Visa fler

Alla övriga publikationer

Conference publication: RADIOTHERAPY AND ONCOLOGY. 2025;206:S1156-S1158
NTCP models for acute bowel toxicity and chemotherapy compliance based on LARC patients treated with 5x5 Gy and chemotherapy in the RAPIDO trial
Tanaka MD; Janssen TM; Schipaanboord BWK; Appelt AL; van Etten B; Hospers GAP; Marijnen CAM; Kranenbarg EM-K; Nilsson PJ; Roodvoets AGH; van de Velde CJH; Valdman A; Glimelius B; Couwenberg AM
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2025;206:S2842-S2843
Hypofractionated and dose-escalated radiotherapy for rectal cancer: a feasibility planning study of proton and photon therapy
Almhagen E; Alkhiat A; Sorcini B; Alpsten F; Valdman A
Conference publication: JOURNAL OF UROLOGY. 2024;211(5):E623
THE IMPACT OF THE TIME ELAPSED BETWEEN PRIMARY TREATMENT AND BCR ON CANCER SPECIFIC MORTALITY IN PATIENTS WHO EXPERIENCED BCR AFTER PRIMARY TREATMENT
Pellegrino F; Falagario UG; Abbadi A; Bjornebo L; Valdman A; Carrieri G; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Lantz A; Wiklund P
Conference publication: JOURNAL OF UROLOGY. 2024;211(5):E1213
PSA RESPONSE AFTER RADIOTHERAPY. IS THERE A DEFINITION OF PSA PERSISTENCE AFTER RT?
Falagario UG; Pellegrino F; Abbadi A; Bjornebo L; Valdman A; Carrieri GG; Briganti A; Montorsi F; Akre O; Aly M; Eklund M; Nordstrom T; Gronberg H; Wiklund P; Lantz A
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2024;194:S1475-S1477
Early safety analysis of hypofractionated proton beam therapy for rectal cancer
Valdman A; Alpsten F; Farlin J; Sorcini B
Conference publication: JOURNAL OF UROLOGY. 2023;209:E214-E215
VALIDATION OF EAU RISK GROUPS FOR BIOCHEMICAL RECURRENCE AFTER RADIOTHERAPY AND RADICAL PROSTATECTOMY FOR PREDICTION OF PROSTATE CANCER MORTALITY
Falagario U; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Lantz A; Wiklund P
Conference publication: JOURNAL OF UROLOGY. 2023;209:E419
PREDICTION OF PROSTATE CANCER SPECIFIC MORTALITY IN MEN UNDERGOING RADIOTHERAPY WITH OR WITHOUT HORMONAL TREATMENT, RISK STRATIFICATION BASED ON CLINICAL CHARACTERISTICS AND PSA TREATMENT RESPONSE
Falagario U; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Wiklund P; Lantz A
Conference publication: EUROPEAN UROLOGY. 2023;83:S379-S380
Validation of EAU Risk groups for biochemical recurrence after radiotherapy and radical prostatectomy for prediction of prostate cancer mortality
Falagario UG; Bogdanovic D; Bjornebo L; Abbadi A; Valdman A; Eklund M; Nordstrom T; Aly M; Gronberg H; Lantz A; Wiklund P
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2022;114(3):E249
Bladder Volumes Matter: Clinical Significance of Bladder Filling in Salvage Radiotherapy for Prostate Cancer
Grodeberg L; Jamtlien S; Koskela LR; Olsson CE; Valdman A
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2021;111(3):E138
A Comparative Study Between AI-Generated, Real-Life Clinical as Well as Reference Rectal Volumes Defined in Accordance With the Swedish National STRONG Guidelines in Prostate Cancer Radiotherapy
Suresh R; Niemela J; Akram S; Valdman A; Olsson CE
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2021;161:S770-S772
Volumes and doses by various ways to define rectum in radiotherapy: clinical, standardized, and AI
Olsson C; Suresh R; Akram S; Niemela J; Valdman A
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2021;161:S1147-S1148
Differences between various rectal volumes and implications for patient-reported rectal toxicity
Pettersson N; Olsson C; Dang T; Olsson I; Valdman A
Review: ACTA ONCOLOGICA. 2020;59(10):1157-1163
A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients
Brandal P; Bergfeldt K; Aggerholm-Pedersen N; Backstrom G; Kerna I; Gubanski M; Bjornlinger K; Evensen ME; Kuddu M; Pettersson E; Brydoy M; Hellebust TP; Dale E; Valdman A; Weber L; Hoyer M
Conference publication: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2019;105(1):E620
Initial Experience with Introducing National Swedish Guidelines for CT- and MRI-based Delineation of Organs at Risk in Radiotherapy: The STRONG Project
Olsson C; Nyholm T; Wieslander E; Zackrisson B; Valdman A
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2019;133:S824-S825
Postoperative radiation therapy following radical prostatectomy in Stockholm County in 2008-2016
Falk J; Aly M; Nordstrom T; Valdman A
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2018;127:S1202-S1203
dosimetric evaluation of carbon-ion beam grid therapy of brain tumors
Tsubouchi T; Valdman A; Siegbahn A
Published conference paper: ACTA ONCOLOGICA. 2017;56(11):1437-1443
Development of an interlaced-crossfiring geometry for proton grid therapy
Henry T; Bassler N; Ureba A; Tsubouchi T; Valdman A; Siegbahn A
Review: BRITISH JOURNAL OF RADIOLOGY. 2017;90(1078):20170073
Microbeam radiation therapy - grid therapy and beyond: a clinical perspective
Schuelke E; Balosso J; Breslin T; Cavaletti G; Djonov V; Esteve F; Grotzer M; Hildebrandt G; Valdman A; Laissue J
Conference publication: MEDICAL PHYSICS. 2017;44(6):3241
Nationwide Collection of Structured RT Data in Sweden
Nyholm T; Olsson C; Skonevik J; Gunnlaugsson A; Valdman A; Johnsson S; Zackrisson B
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2017;123:S959
Evaluation of proton grid therapy in challenging clinical cases
Henry T; Valdman A; Siegbahn A
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2017;123:S953
Proton grid therapy (PGT): a parameter study
Henry T; Valdman A; Siegbahn A
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2016;119:S260
The development of proton-beam grid therapy (PBGT)
Henry T; Valdman A; Siegbahn A
Conference publication: MODERN PATHOLOGY. 2009;22:171A
Prostate Atrophy, but Not Prostate Carcinoma, Is Characterised by a Relative Infiltration of Tregs
Gurel B; Valdman A; Cappelli L; Tsilidis K; Hicks J; De Marzo AM; Drake CG; Meeker AK
Conference publication: LABORATORY INVESTIGATION. 2009;89:171A
Prostate Atrophy, but Not Prostate Carcinoma, Is Characterised by a Relative Infiltration of Tregs
Gurel B; Valdman A; Cappelh I; Tahda K; Hicks I; De Marza AM; Draka CG; Mecker IA
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2008;88:S315-S316
CLINICAL OUTCOME IN PATIENTS WITH PROSTATE CANCER TREATED WITH HIGH DOSE-RATE 192-IRIDIUM BRACHYTHERAPY AS MONOTHERAPY
Ryberg M; Castellanos E; Hjelm-Eriksson M; Cohn-Cedermark G; Valdman A; Ullen A; Nilsson J; Lundell M; Lundell G; Nilsson S; Kalkner KM
Conference publication: RADIOTHERAPY AND ONCOLOGY. 2008;88:S185
COMBINED EXTERNAL RADIOTHERAPY AND HIGH DOSE RATE BRACHYTHERAPY BOOST OF RELAPSING UROEPITHELIAL CANCER IN THE REMAINING URETER
Kalkner KM; Bengtsson E; Valdman A; Ullen A; Sward J; Brehmer M
Conference publication: EUROPEAN UROLOGY OPEN SCIENCE. 2008;7(3):252
Clinical signification of intratumoural CD8+CD25+ regulatory T (Treg) cells in prostate carcinoma
Comperat EM; Egevald L; Roupret M; Vaessen C; Valdman A; Jonmarker S; Richard F; Capron F; Charlotte F
Conference publication: MODERN PATHOLOGY. 2008;21:157A
Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer
Gloessgen A; Jonmarker S; Nilsson B; Lewensohn R; Ekman P; Valdman A; Egevad L
Conference publication: MODERN PATHOLOGY. 2008;21:186A
Distribution of FOXP3, CD4 and CD8 positive lymphocytic cells in benign and malignant prostatic tissues
Valdman A; Jonmarker S; Rosenblatt R; Comperat E; Charlotte F; Roupert M; Pisa P; Egevad L
Conference publication: LABORATORY INVESTIGATION. 2008;88:186A
Distribution of FOXP3, CD4 and CD8 positive lymphocytic cells in benign and malignant prostatic tissues
Valdman A; Jonmaker S; Rosenblatt R; Comperat E; Charlotte F; Roupert M; Pisa P; Egevad L
Review: TUMOR BIOLOGY. 2008;29(5):311-322
Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer
Rosenblatt R; Jonmarker S; Lewensohn R; Egevad L; Sherif A; Kalkner KM; Nilsson S; Valdman A; Ullen A
Doctoral thesis: 2005
A study of the transition from premalignancy to clinical prostate cancer
Valdman A
Conference publication: PROCEEDINGS OF SPIE - THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING. 2003;:49-54
The effects of visual fluorescence marking induced by 5-aminolevulinic acid for endoscopic diagnosis of urinary bladder cancer
Daniltchenko DI; Koenig F; Schnorr D; Valdman A; Al-Shukri S; Loening SA
Conference publication: JOURNAL OF UROLOGY. 2003;169(4):121
Characterization of significantly overexpressed genes identified by high throughput CDNA microarrays as new biomarkers in prostate cancer
Li CD; Lapointe J; Egevad L; Fang XL; Valdman A; Brooks J; Botstein D; Ekman PE; Pollack JR; Brown PO
Conference publication: JOURNAL OF UROLOGY. 2003;169(4):385
The T/T genotype of SNP33978 in the BRG1 gene is associated with early onset of highly malignant prostate cancer
Valdman A; Nordenskjöldd A; Fang XL; Naito A; Salman AS; Larsson C; Ekman PE; Li CD
Visa fler

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2025-2027
Senior Forskningsspecialist, Onkologi-Patologi, Karolinska Institutet, 2022-2024

Examina och utbildning

Docent, Onkologi, Karolinska Institutet, 2021
MEDICINE DOKTORSEXAMEN, Institutionen för molekylär medicin och kirurgi, Karolinska Institutet, 2005
LICENTIATEXAMEN, INST F KIRURGISK VETENSKAP (K3), Karolinska Institutet, 2003

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI